1078 West Baltimore Pike
Media, PA 19063
(484) 227-4350
(484) 227-4677 fax
Most Recent Peer-reviewed Publications
- Opportunities and challenges in the era of molecularly targeted agents and radiation therapy
- ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma
- ALK inhibitor PF02341066 (Crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK
- Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects.
- Higher Levels of c-Met Expression and Phosphorylation Identify Cell Lines With Increased Sensitivity to AMG-458, a Novel Selective c-Met Inhibitor With Radiosensitizing Effects
Medical School
Shanghai Medical University, Peoples Republic of China - 1987
Residency
University of California School of Medicine
Fellowship
University of Rochester Medicine & Dentistry, NY
Board Certification
Radiation Oncology
Hospital Appointment
Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital
Research and Clinical Interests
Dr. Bo Lu is a board-certified Radiation Oncologist who comes to Jefferson from Vanderbilt University in Nashville, Tenn., where he was an Ingram associate professor with tenure in the Department of Radiation Oncology and Cancer Biology of the University’s School of Medicine. He was also an attending radiation oncologist at the Vanderbilt University Medical Center, member of the Ingram Cancer Center, and director of the Translational Research Program and Lung Cancer Research Program. Dr. Lu received his Ph.D. in Cell and Molecular Biology from Baylor School of Medicine in Houston and his Doctorate in Medicine from Shanghai Medical University in China. Dr. Lu completed his residency in radiation oncology at the University of Southern California, School of Medicine. Dr. Lu’s focus is on radiation-induced cell death in lung patients, among other basic science areas. His clinical interests include the integration of novel targeted agents in the treatment of lung cancer, radiosurgery for lung cancer, and reduction of toxicities from thoracic radiation. More recently, Dr. Lu has looked at cancer stem cells for enhancing radiotherapy in a setting of lung cancer.